Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...

Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “neutral” rating reiterated by equities research analysts at Piper ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

Piper Sandler analyst David Amsellem lowered the firm’s price target on Biogen (BIIB) to $135 from $138 and keeps a Neutral rating on the ...

Biogen (BIIB) and Stoke Therapeutics (STOK) announced a collaboration for the development and commercialization of zorevunersen, a potential ...

Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a ...

Biogen (NASDAQ:BIIB – Free Report) had its price target trimmed by HC Wainwright from $300.00 to $241.00 in a report issued ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update.

Biogen Inc. (BIIB) reported $2.45 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 2.9%. EPS of $3.44 for the same period compares to $2.95 a year ago.